Cover Image
市場調查報告書

東南亞的第二型糖尿病治療藥的市場

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

出版商 GBI Research 商品編碼 369233
出版日期 內容資訊 英文 202 Pages
訂單完成後即時交付
價格
Back to Top
東南亞的第二型糖尿病治療藥的市場 Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
出版日期: 2017年10月01日 內容資訊: 英文 202 Pages
簡介

第二型糖尿病的治療方法這10年來飛躍性地進步,尤其是新治療藥不斷上市變。治療選擇也很廣泛,提供各種標的對象的治療藥。儘管如此,關於血糖管理和併發症 (糖尿病性神經症、視網膜症、心血管疾病等)的預防、治療,仍存在著巨大的未滿足需求。

本報告提供東南亞各國的第二型糖尿病 (T2DM) 治療藥的市場現況與未來展望相關分析,第二型糖尿病概要、特性,及現在已上市的產品概要,現在臨床實驗中的開發中產品一覽和臨床實驗的進展,今後的市場成長、技術開發 (臨床實驗進展)的預測,主要企業的概要與競爭策略,今後的資本交易、產業重組預測等相關調查與考察。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 流行病學
  • 症狀
  • 病因、病理生理學
  • 診斷方法
  • 分類
  • 預後
  • 治療選擇
    • 治療流程
    • 非胰島素療法
    • 胰島素療法
  • 治療方法的分類
    • 非胰島素療法
    • 胰島素療法
  • 共生病症和併發症

第3章 已上市產品

  • 概要
  • 雙胍類系
    • Metformin
  • 磺醯尿素類
  • 胰島素增敏劑
    • PIOGLITAZONE
    • Duvie (robeguritazon) - Chong Kun Dang
  • GLP-1受體激動劑
    • Byetta (exenatide) - Eli Lilly
    • Bydureon (exenatide) - AstraZeneca
    • Victoza (liraglutide) - Novo Nordisk
    • Lyxumia (lixisenatide) - Sanofi
    • Tanzeum (albiglutide) - GlaxoSmithKline
  • DPP-4抑制劑
    • Januvia (sitagliptin) - Merck
    • Galvus (vildagliptin) - Novartis
    • Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca
    • Trajenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca
    • Zemiglo (gemigliptin) - LG Life Sciences
    • Suganon (evogliptin) - Dong-A ST
    • Gadret (anagliptin) - JW Pharmaceutical
    • Nesina (alogliptin) - Takeda
    • Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma
  • SGLT-2抑制劑
    • Forxiga (dapagliflozin) - AstraZeneca
    • Invokana (canagliflozin) - Janssen
    • Jardiance (empagliflozin) - Boehringer Ingelheim
    • Suglat (ipragliflozin) - Astellas
  • 胰島素療法
    • Lantus (Insulin glargine) - Sanofi
    • Levemir (Insulin Detemir) - Novo Nordisk
    • Tresiba (Insulin Degludec) - Novo Nordisk
    • Toujeo (insulin glargine) - Sanofi
  • 已上市產品的相對的功效、安全性

第4章 開發中產品

  • 概要
  • 開發中產品一覽:臨床實驗的各階段,各分子類型,各投藥途徑,計劃的各類型
  • 開發中產品一覽:各分子標的
  • 有前途的開發平台(管線)候補藥
    • NN-9535(subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk
    • Trulicity (dulaglutide)
    • Ertugliflozin - Pfizer
    • Bexagliflozin - Theracos
    • Omarigliptin - Merck
  • 開發中產品的產品相對功效、安全性
  • 產品競爭的組成架構

第5章 臨床實驗分析

  • 失敗率
    • 整體失敗率
    • 各相位、各分子類型的失敗率
    • 各相位、各分子標的失敗率
  • 臨床實驗的規模
  • 臨床實驗的期間
    • 臨床實驗期間:各開發階段、各分子類型
    • 臨床實驗期間:各開發階段、各分子標的
  • 臨床實驗的相關指標:摘要

第6章 多方案預測

  • 各地區市場
  • 東南亞市場
  • 韓國
    • 治療藥的利用模式
    • 年度治療費用
    • 市場規模
  • 新加坡
  • 台灣
  • 馬來西亞
  • 菲律賓
  • 泰國
  • 越南
  • 印尼

第7章 市場動態 (促進、阻礙因素)

  • 推動市場要素
    • 人口高齡化,肥胖人口的增加,經濟發展
    • 對第二型糖尿病的知識擴大
    • 認證藥物類別的連續性的上市、普及
    • 臨床實驗的最後階段有潛力的開發中產品,改變治療範例的可能性
    • 聯合治療的利用擴大
  • 市場阻礙因素
    • 非藥理性的一次選擇治療
    • 非專利醫藥品的使用擴大
    • 治療方針的遵守度低
    • 專利到期伴隨的產品的一般化、利益消失

第8章 資本交易與業界重組

  • 授權合約交易
    • 各地區的交易趨勢/金額
    • 年度交易量及總合交易金額的變化
    • 各臨床實驗階段、各分子類型、各分子標的交易金額
    • 主要的授權合約交易
  • 共同開發交易

第9章 附錄

  • 全開發中產品:各相位
  • 各國市場的未來預測 (到2022年)
  • 參考文獻
  • 簡稱一覽
  • 分析方法
  • 聯絡處資訊
  • 免責聲明

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GBIHC456MR

Executive Summary

Diabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both (ADA, 2014b). Insulin is a hormone that contributes to the regulation of blood glucose levels by stimulating the uptake of glucose by cells for energy. Consequently, insufficient insulin activity results in chronic hyperglycemia, which is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels.

Market for type 2 diabetes mellitus (T2DM) is expected to grow from $1.92 billion in 2016 to $2.96 billion in 2023, at a compound annual growth rate (CAGR) of 6.3%. This growth will be driven by the rapidly expanding prevalence population, due to increasingly aging populations and sedentary lifestyles, as well as an increase in diagnosis and treatment rates, due to rising disease awareness among the public. The increased uptake of recently approved and emerging branded therapeutics, in favor of lower-cost generic products, will also propel market growth.

Pipeline for T2DM is large, with 609 products at a disclosed stage of development, although the majority of these drugs are at an early stage. About 52% of the pipeline is in the Preclinical stage, while 17% is in the Discovery stage. Though 28% of the pipeline is in clinical development, only 2% is in the Pre-registration stage. The late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes compared with currently marketed products. By 2023, Novo Nordisk's OG-217SC (oral semaglutide) is expected to be in the market.

The top-selling drugs presently - Januvia, Victoza, Novolog, and Invokana - are expected to remain dominant within the disease cluster and are all - along with many other top-selling products - indicated for T2DM. However, three of the anticipated top 10 best-selling drugs of 2023 will be new to the South-East Asia market.

The report "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" covers epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications of type 2 diabetes mellitus (T2DM),

In depth, this report provides the following -

  • Provides an overview of the T2DM marketed products landscape, including product profiles of key marketed products and heatmaps that compare the safety and efficacy parameters of the various drugs.
  • Analyzes the T2DM pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
  • Provides detailed analysis of recent clinical trials in T2DM by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the T2DM market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2016-2023 period. The eight South-East Asia markets are covered and data are presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for T2DM in South-East Asia markets.
  • Describes the major deals that have taken place in the global T2DM market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value. Licensing and co-development deals by region are also included.

Companies mentioned in this report: Pfizer, Theracos, Merck & Co., Sanofi.

Scope

The current T2DM market in South-East Asia contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.

What are the competitive advantages of the existing novel drugs?

There are over 609 active pipeline molecules, with most of the late-stage investigational drug candidates featuring improved dosing regimens and administration routes compared with currently marketed products and combination therapies.

Which classes of novel drugs are most prominent in the pipeline?

Is there potential for pipeline molecules to address unmet needs within the T2DM market?

Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 62.1%, with the overall attrition rate for T2DM standing at 88.3%.

How do failure rates vary by product stage of development, molecule type, and mechanism of action?

How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2016-2023 forecast period, the T2DM therapeutics market in South-East Asia is expected to increase in value at a CAGR of 6.3%, from $1.92 billion to over $2.96 billion.

Which markets make the most significant contribution to the regional market size?

What are the epidemiology trends in these markets?

Will new market entrants lead to substantial changes in annual therapy costs?

How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

  • Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed product landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
  • Discover trends in licensing and co-development deals concerning T2DM products, and identify the major strategic consolidations that have shaped the commercial landscape.

1 Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 7
  • 1.2 List of Figures 7

2 Introduction 10

  • 2.1 Disease Introduction 10
  • 2.2 Epidemiology 11
  • 2.3 Symptoms 11
  • 2.4 Etiology and Pathophysiology 12
  • 2.5 Diagnosis 14
  • 2.6 Classification 16
  • 2.7 Prognosis 17
  • 2.8 Treatment Options 17
    • 2.8.1 Treatment Algorithm 18
    • 2.8.2 Non-insulin T2DM Therapies 20
    • 2.8.3 Insulin T2DM Therapies 23
  • 2.9 Treatment Segments 25
    • 2.9.1 Non-Insulin Therapies 25
    • 2.9.2 Insulin Therapies 41
  • 2.10 Co-morbidities and Complications 44
  • 2.11 Non-pharmacological Treatments 46
    • 2.11.1 Dietary Interventions 46
    • 2.11.2 Exercise 46

3 Marketed Products 47

  • 3.1 Overview 47
  • 3.2 Biguanides 48
    • 3.2.1 Metformin 48
  • 3.3 Sulfonylureas 49
  • 3.4 Thiazolidinediones 51
    • 3.4.1 Pioglitazone 51
    • 3.4.2 Duvie (lobeglitazone) - Chong Kun Dang 52
  • 3.5 GLP-1 Receptor Agonists 52
    • 3.5.1 Byetta (exenatide) - AstraZeneca 52
    • 3.5.2 Bydureon (exenatide) - AstraZeneca 53
    • 3.5.3 Victoza (liraglutide) - Novo Nordisk 55
    • 3.5.4 Lyxumia (lixisenatide) - Sanofi 56
    • 3.5.5 Tanzeum (albiglutide) - GlaxoSmithKline 58
    • 3.5.6 Trulicity (dulaglutide) - Eli Lilly 59
  • 3.6 DPP-4 Inhibitors 60
    • 3.6.1 Januvia (sitagliptin) - Merck & Co. 60
    • 3.6.2 Galvus (vildagliptin) - Novartis 62
    • 3.6.3 Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca 63
    • 3.6.4 Tradjenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca 64
    • 3.6.5 Zemiglo (gemigliptin) - LG Life Sciences 65
    • 3.6.6 Suganon (evogliptin) - Dong-A ST 66
    • 3.6.7 Gadret (anagliptin) - JW Pharmaceutical 67
    • 3.6.8 Nesina (alogliptin) - Takeda 67
    • 3.6.9 Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma 68
  • 3.7 SGLT-2 Inhibitors 69
    • 3.7.1 Forxiga (dapagliflozin) - AstraZeneca 69
    • 3.7.2 Invokana (canagliflozin) - Janssen 71
    • 3.7.3 Jardiance (empagliflozin) - Boehringer Ingelheim 72
    • 3.7.4 Suglat (ipragliflozin) - Astellas 73
  • 3.8 Insulin Therapies 74
    • 3.8.1 Lantus (insulin glargine) - Sanofi 74
    • 3.8.2 Levemir (insulin detemir) - Novo Nordisk 75
    • 3.8.3 Tresiba (insulin degludec) - Novo Nordisk 76
    • 3.8.4 Toujeo (insulin glargine) - Sanofi 77
  • 3.9 Comparative Efficacy and Safety of Marketed Products 78

4 Pipeline Analysis 84

  • 4.1 Overview 84
  • 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 85
  • 4.3 Pipeline by Molecular Target 87
  • 4.4 Promising Pipeline Molecules 91
    • 4.4.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk 91
    • 4.4.2 Ertugliflozin - Pfizer 95
    • 4.4.3 Bexagliflozin - Theracos 96
    • 4.4.4 Omarigliptin - Merck & Co. 97
    • 4.4.5 Sotagliflozin- Sanofi 99
  • 4.5 Comparative Efficacy and Safety of Pipeline Products 101
  • 4.6 Product Competitive Framework 102

5 Clinical Trial Analysis 105

  • 5.1 Failure Rate 105
    • 5.1.1 Overall Failure Rate 105
    • 5.1.2 Failure Rate by Phase and Molecule Type 107
    • 5.1.3 Failure Rate by Phase and Molecular Target 107
  • 5.2 Clinical Trial Duration 108
    • 5.2.1 Trial Duration by Molecule Type and Stage of Development 108
    • 5.2.2 Trial Duration by Molecular Target and Stage of Development 109
  • 5.3 Clinical Trial Size 110
    • 5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 110
    • 5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 113
  • 5.4 Summary of Clinical Trial Metrics 114

6 Multi-Scenario Forecast 116

  • 6.1 Geographical Markets 116
  • 6.2 South-East Asia Markets 116
  • 6.3 South Korea 119
    • 6.3.1 Treatment Usage Patterns 119
    • 6.3.2 Annual Cost of Therapy 120
    • 6.3.3 Market Size 120
  • 6.4 Singapore 121
    • 6.4.1 Treatment Usage Patterns 121
    • 6.4.2 Annual Cost of Therapy 122
    • 6.4.3 Market Size 123
  • 6.5 Taiwan 123
    • 6.5.1 Treatment Usage Patterns 123
    • 6.5.2 Annual Cost of Therapy 124
    • 6.5.3 Market Size 125
  • 6.6 Malaysia 125
    • 6.6.1 Treatment Usage Patterns 125
    • 6.6.2 Annual Cost of Therapy 126
    • 6.6.3 Market Size 127
  • 6.7 Philippines 127
    • 6.7.1 Treatment Usage Patterns 127
    • 6.7.2 Annual Cost of Therapy 128
    • 6.7.3 Market Size 129
  • 6.8 Thailand 130
    • 6.8.1 Treatment Usage Patterns 130
    • 6.8.2 Annual Cost of Therapy 131
    • 6.8.3 Market Size 132
  • 6.9 Vietnam 132
    • 6.9.1 Treatment Usage Patterns 132
    • 6.9.2 Annual Cost of Therapy 133
    • 6.9.3 Market Size 134
  • 6.10 Indonesia 135
    • 6.10.1 Treatment Usage Patterns 135
    • 6.10.2 Annual Cost of Therapy 136
    • 6.10.3 Market Size 137

7 Drivers and Barriers 138

  • 7.1 Drivers 138
    • 7.1.1 Aging Population, Increasing Obesity and Growing Economy 138
    • 7.1.2 Increasing Awareness of T2DM 138
    • 7.1.3 Continued Uptake of Recently Approved Drug Classes 138
    • 7.1.4 Promising Late-Stage Pipeline Products Can Change the Treatment Paradigm 138
    • 7.1.5 Enhanced Usage of Combination Therapies 139
  • 7.2 Barriers 139
    • 7.2.1 Non-pharmacological First-line Treatment 139
    • 7.2.2 Widespread Usage of Generic Drugs 139
    • 7.2.3 Poor Adherence to Treatment Regimens 139
    • 7.2.4 Generic Erosion Resulting from Patent Expirations 139

8 Deals and Strategic Consolidations 140

  • 8.1 Licensing Deals 140
    • 8.1.1 Deals by Region and Value 140
    • 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 141
    • 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 142
    • 8.1.4 Key Licensing Deals 145
  • 8.2 Co-development Deals 148
    • 8.2.1 Deals by Region and Value 148
    • 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 149
    • 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 151
    • 8.2.4 Key Co-development Deals 153

9 Appendix 157

  • 9.1 All Pipeline Drugs by Stage of Development 157
    • 9.1.1 Discovery 157
    • 9.1.2 Preclinical 161
    • 9.1.3 IND/CTA-filed 172
    • 9.1.4 Phase I 173
    • 9.1.5 Phase II 175
    • 9.1.6 Phase III 178
    • 9.1.7 Pre-registration 179
  • 9.2 Summary of Multi-Scenario Market Forecasts to 2023 179
    • 9.2.1 South-East Asia 179
    • 9.2.2 South Korea 180
    • 9.2.3 Singapore 180
    • 9.2.4 Taiwan 181
    • 9.2.5 Malaysia 181
    • 9.2.6 Philippines 182
    • 9.2.7 Thailand 182
    • 9.2.8 Vietnam 183
    • 9.2.9 Indonesia 183
  • 9.3 Bibliography 184
  • 9.4 Abbreviations 196
  • 9.5 Research Methodology 198
    • 9.5.1 Secondary Research 198
    • 9.5.2 Marketed Product Profiles 199
    • 9.5.3 Late-Stage Pipeline Candidates 199
    • 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 199
    • 9.5.5 Product Competitiveness Framework 199
    • 9.5.6 Pipeline Analysis 200
    • 9.5.7 Forecasting Model 201
    • 9.5.8 Deals Data Analysis 201
  • 9.6 Contact Us 202
  • 9.7 Disclaimer 202

1.1 List of Tables

  • Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy 29
  • Table 2: T2DM Therapeutics Market, Global, Licensing Deals Valued over $50m, 2006-April 2017 147
  • Table 3: T2DM Therapeutics Market, Global, Licensing Deals Valued over $100m, 2006-April 2017 155
  • Table 4: T2DM Therapeutics, Global, All Pipeline Products, Discovery, April 2017 157
  • Table 5: T2DM Therapeutics, Global, All Pipeline Products, Preclinical, April 2017 161
  • Table 6: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed, April 2017 172
  • Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase I, April 2017 173
  • Table 8: T2DM Therapeutics, Global, All Pipeline Products, Phase II, April 2017 175
  • Table 9: T2DM Therapeutics, Global, All Pipeline Products, Phase III, April 2017 178
  • Table 10: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration, April 2017 179
  • Table 11: T2DM Therapeutics Market, South-East Asia, Market Forecast, 2016-2023 179
  • Table 12: T2DM Therapeutics Market, South Korea, Market Forecast, 2016-2023 180
  • Table 13: T2DM Therapeutics Market, Singapore, Market Forecast, 2016-2023 180
  • Table 14: T2DM Therapeutics Market, Taiwan, Market Forecast, 2016-2023 181
  • Table 15: T2DM Therapeutics Market, Malaysia, Market Forecast, 2016-2023 181
  • Table 16: T2DM Therapeutics Market, Philippines, Market Forecast, 2016-2023 182
  • Table 17: T2DM Therapeutics Market, Thailand, Market Forecast, 2016-2023 182
  • Table 18: T2DM Therapeutics Market, Vietnam, Market Forecast, 2016-2023 183
  • Table 19: T2DM Therapeutics Market, Indonesia, Market Forecast, 2016-2023 183
  • Table 20: Abbreviations 196

1.2 List of Figures

  • Figure 1: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Anti-diabetic Marketed Products 79
  • Figure 2: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for GLP-1 Receptor 80
  • Figure 3: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for DPP-4 inhibitors 81
  • Figure 4: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for SGLT-2 Inhibitors 82
  • Figure 5: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for Insulin Therapy 83
  • Figure 6: T2DM Therapeutics Market, Global, Pipeline, 2017 86
  • Figure 7: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2017 90
  • Figure 8: T2DM Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2017 91
  • Figure 9: T2DM Therapeutics Market, South-East Asia, NN-9535 Forecast ($m), 2018-2023 94
  • Figure 10: T2DM Therapeutics Market, South-East Asia, OG-217SC Forecast ($m), 2020-2023 94
  • Figure 11: T2DM Therapeutics Market, South-East Asia, Ertugliflozin Forecast ($m), 2018-2023 96
  • Figure 12: T2DM Therapeutics Market, South-East Asia, Bexagliflozin Forecast ($m), 2020-2023 97
  • Figure 13: T2DM Therapeutics Market, South-East Asia, Omarigliptin Forecast ($m), 2017-2023 99
  • Figure 14: T2DM Therapeutics Market, South-East Asia, Sotagliflozin Forecast ($m), 2021-2023 100
  • Figure 15: T2DM Therapeutics Market, South-East Asia, Heatmap for Pipeline Products, April 2017 102
  • Figure 16: T2DM Therapeutics Market, South-East Asia, Competitor Matrix for Marketed and Pipeline Products, April 2017 104
  • Figure 17: T2DM Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2017 106
  • Figure 18: T2DM Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2017 107
  • Figure 19: T2DM Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2017 108
  • Figure 20: T2DM Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2017 109
  • Figure 21: T2DM Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2017 110
  • Figure 22: T2DM Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2017 111
  • Figure 23: T2DM Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2017 112
  • Figure 24: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2017 113
  • Figure 25: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-2017 114
  • Figure 26: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Type 115
  • Figure 27: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 115
  • Figure 28: T2DM Therapeutics Market, South-East Asia, Treatment Usage Patterns (million), 2016-2023 117
  • Figure 29: T2DM Therapeutics Market, South-East Asia, Market Size ($bn), 2016-2023 118
  • Figure 30: T2DM Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2016-2023 119
  • Figure 31: T2DM Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023 120
  • Figure 32: T2DM Therapeutics Market, South Korea, Market Size ($m), 2016-2023 121
  • Figure 33: T2DM Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2016-2023 122
  • Figure 34: T2DM Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2016-2023 122
  • Figure 35: T2DM Therapeutics Market, Singapore, Market Size ($m), 2016-2023 123
  • Figure 36: T2DM Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2016-2023 124
  • Figure 37: T2DM Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2016-2023 124
  • Figure 38: T2DM Therapeutics Market, Taiwan, Market Size ($m), 2016-2023 125
  • Figure 39: T2DM Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2016-2023 126
  • Figure 40: T2DM Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2016-2023 126
  • Figure 41: T2DM Therapeutics Market, Malaysia, Market Size ($m), 2016-2023 127
  • Figure 42: T2DM Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2016-2023 128
  • Figure 43: T2DM Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2016-2023 129
  • Figure 44: T2DM Therapeutics Market, Philippines, Market Size ($m), 2016-2023 130
  • Figure 45: T2DM Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2016-2023 131
  • Figure 46: T2DM Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2016-2023 131
  • Figure 47: T2DM Therapeutics Market, Thailand, Market Size ($m), 2016-2023 132
  • Figure 48: T2DM Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2016-2023 133
  • Figure 49: T2DM Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2016-2023 134
  • Figure 50: T2DM Therapeutics Market, Vietnam, Market Size ($m), 2016-2023 135
  • Figure 51: T2DM Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2016-2023 136
  • Figure 52: T2DM Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2016-2023 136
  • Figure 53: T2DM Therapeutics Market, Indonesia, Market Size ($m), 2016-2023 137
  • Figure 54: T2DM Therapeutics, Global, Licensing Deals by Region and Value, 2006- April 2017 141
  • Figure 55: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006- April 2017 142
  • Figure 56: T2DM Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-April 2017 143
  • Figure 57: T2DM Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006- April 2017 144
  • Figure 58: T2DM Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-April 2017 145
  • Figure 59: T2DM Therapeutics Market, Global, Co-development Deals by Value ($m), 2006-April 2017 149
  • Figure 60: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006- April 2017 150
  • Figure 61: T2DM Therapeutics Market, Global, Co-development Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-April 2017 151
  • Figure 62: T2DM Therapeutics Market, Global, Co-development Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-April 2017 152
  • Figure 63: T2DM Therapeutics Market, Global, Co-development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-April 2017 153
Back to Top